Pharma Mar SA 2017 SR
The report highlights Pharma Mar Group's significant commitment to research and development, investing 42% of its revenues into R&D, particularly in oncology and ophthalmology. The company maintains a stable workforce with over 93% of employees on indefinite contracts and a strong representation of women in management roles. Environmental stewardship is a priority, with major subsidiaries PharmaMar and Xylazel achieving ISO 14001 certification and implementing measures to reduce energy and water consumption. The group also emphasizes ethical clinical trials and active community engagement through scientific sponsorships and patient group collaborations.
Company: Pharma Mar SA
Sector: Manufacturing
Country: Spain
Year: 2017
Type: SR
Pages: 76
Back to company
Pharma Mar SA
Corporate Social Responsibility Report
The report highlights Pharma Mar Group's significant commitment to research and development, investing 42% of its revenues into R&D, particularly in oncology and ophthalmology. The company maintains a stable workforce with over 93% of employees on indefinite contracts and a strong representation of women in management roles. Environmental stewardship is a priority, with major subsidiaries PharmaMar and Xylazel achieving ISO 14001 certification and implementing measures to reduce energy and water consumption. The group also emphasizes ethical clinical trials and active community engagement through scientific sponsorships and patient group collaborations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees